Aripiprazole Solution
Product Images NDC 59651-110

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 59651-110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)

A bar graph illustrating the effects of various drugs on aripiprazole pharmacokinetics, showing fold changes with 90% confidence intervals in AUC and Cmax values relative to a reference without interacting drugs. It includes categories such as CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs like valproate, lithium, and lorazepam.*

FDA Label Image

Package Label-principal Display Panel (1 mg/mL (150 mL Carton Label))

Label for Aripiprazole Oral Solution 1 mg/mL by Aurobindo Pharma Limited. The 150 mL bottle label states the drug contains 1 mg of aripiprazole per mL in aqueous solution. It includes storage instructions at 20° to 25°C and a caution not to use if tamper-evident seal is broken. The label shows distributor information as Aurobindo Pharma USA, Inc., and indicates the product is made in India.*

FDA Label Image

Aripiprazole Fig11

Aripiprazole Oral Solution 1 mg/mL packaging label showing the product name, strength, oral solution dosage form, and bottle size of 150 mL. The label includes storage instructions, dosing cup info, pharmacist dispensing information, and distributor details for Aurobindo Pharma USA, Inc. The label also features the Aurobindo logo and barcodes.*

FDA Label Image

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)

A chart illustrating the effects of various drugs on dehydro-aripiprazole pharmacokinetics, showing fold changes and 90% confidence intervals for AUC and Cmax. The x-axis represents the change relative to reference without interacting drug, and the y-axis lists interacting drugs grouped by type, such as CYP3A4 inhibitors and inducers, gastric acid blockers, and others.*

FDA Label Image

Figure 3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)

A scatter plot figure illustrating the effects of aripiprazole on the pharmacokinetics of various other drugs. It shows fold changes and 90% confidence intervals for metrics such as AUC, Cmax, INR, and DMWDRP for different drugs like dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference without interacting drug.*

FDA Label Image

Figure 4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)

A figure titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing fold change with 90% confidence intervals for aripiprazole pharmacokinetic measures (AUC and Cmax) across special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, relative to reference values.*

FDA Label Image

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)

A pharmacokinetic chart illustrating the effects of intrinsic factors on dehydro-aripiprazole levels. It compares fold changes and 90% confidence intervals in AUC and Cmax across groups defined by CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and renal impairment (severe). The x-axis shows change relative to reference values.*

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

A Kaplan-Meier plot showing the cumulative proportion of patients with relapse in a schizophrenia study comparing Aripiprazole to placebo over 182 days. The graph displays the proportion with relapse on the Y-axis and days from randomization on the X-axis, with separate curves for Aripiprazole and placebo, and the number of subjects at risk listed below the X-axis at various time points.*

FDA Label Image

Figure 7: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (bipolar Study 7) (Aripiprazole Fig7)

Kaplan-Meier curve showing cumulative proportion of patients with relapse over time from randomization in a bipolar study. The graph compares Aripiprazole to placebo, with proportion with relapse on the y-axis and days from randomization on the x-axis. The number of subjects at risk is listed below the x-axis for each group at various time points.*

FDA Label Image

Figure 8: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse To Any Mood Event (bipolar Study 8) (Aripiprazole Fig8)

Kaplan-Meier curve displaying the cumulative proportion of patients experiencing relapse to any mood event over days from randomization, comparing Aripiprazole and placebo groups in a bipolar study. The y-axis represents the proportion with relapse, and the x-axis shows days from 0 to 364, with numbers of subjects at risk listed below the timeline for both groups.*

FDA Label Image

Package Label-principal Display Panel 1 mg/ml (150 mL Bottle) (Aripiprazole Fig9)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment comparing Aripiprazole low dose, Aripiprazole high dose, and placebo groups. The graph illustrates least-squares mean changes, with tic scores decreasing more for both Aripiprazole doses compared to placebo over time.*

FDA Label Image

Chemical Structure (Aripiprazole Str)

Chemical structure diagram of aripiprazole showing the arrangement of atoms and bonds within the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.